AstraZeneca collaborates on cancer nanomedicine

04/22/2013 | PharmaTimes (U.K.)

AstraZeneca and Bind Therapeutics will collaborate on a targeted, programmable, nanotechnology cancer treatment involving a kinase inhibitor. The nanoparticles, which Bind calls Accurins, selectively accumulate, causing higher drug concentrations at the site of a tumor while sparing healthy tissue. AstraZeneca is also working with Horizon Discovery on a kinase therapy that targets the K-Ras mutation in various cancers, including of the lung and colon.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY